Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The company is headquartered in Newtown, Pennsylvania and currently employs 21 full-time employees. The company went IPO on 2014-06-27. The firm is engaged in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS), is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy utilizes the PoNS device in conjunction with supervised therapeutic exercise. The PoNS Therapy consists of condition-specific exercises for movement control, including balance and gait training and breathing and awareness training, which are tailored to focus on the individual patient’s functional deficits.
Follow-Up Questions
Helius Medical Technologies Inc의 CEO는 누구입니까?
Mr. Dane Andreeff은 2017부터 회사에 합류한 Helius Medical Technologies Inc의 President입니다.
HSDT 주식의 가격 성능은 어떻습니까?
HSDT의 현재 가격은 $4.53이며, 전 거래일에 decreased 0.43% 하였습니다.
Helius Medical Technologies Inc의 주요 사업 주제나 업종은 무엇입니까?
Helius Medical Technologies Inc은 Health Care 업종에 속하며, 해당 부문은 Health Care입니다
Helius Medical Technologies Inc의 시가총액은 얼마입니까?
Helius Medical Technologies Inc의 현재 시가총액은 $176.2M입니다
Helius Medical Technologies Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Helius Medical Technologies Inc에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 0명의 매수, 3명의 보유, 1명의 매도, 그리고 0명의 강력한 매도를 포함합니다